SCHEMBL5461908

SCHEMBL5461908

COC(=O)c1ccc(NC=O)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.64
CA12 O43570 3/20 0.59
CA1 P00915 3/20 0.59
CA2 P00918 3/20 0.59
CA7 P43166 3/20 0.59
CA9 Q16790 3/20 0.59
CA14 Q9ULX7 3/20 0.59
PDK2 Q15119 1/20 0.59
PDK4 Q16654 1/20 0.59
GAA P10253 2/20 0.56
EGFR P00533 3/20 0.52
MYC P01106 1/20 0.49
LMNA P02545 1/20 0.49
TSHR P16473 1/20 0.49
EPHX2 P34913 1/20 0.48
PTGS2 P35354 1/20 0.42
RAB9A P51151 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29818874 0.86 SMN1; SMN2 (0.46) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL26908145 0.86 SMN1; SMN2 (0.46) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL18115703 0.82 KLK1 (0.44) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL2342749 0.82 ABL1 (0.45) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL5460241 0.82 TDP1 (0.48) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL7331267 0.81 SMN1; SMN2 (0.70) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL7635128 0.81 KMT2A (0.56) CA12CA1CA2CA7CA9
SCHEMBL8539913 0.80 CA2 (0.55) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL23468922 0.79 EGFR (0.51) SMN1; SMN2GAAEGFRLMNATSHR
SCHEMBL28043705 0.79 POLB (0.65) SMN1; SMN2CA9EGFRTSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SMN1; SMN2 2862/4885CA12 2735/4885CA1 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.